tetano
Editor, Senior Moderator
Blood Adv
. 2021 Jul 13;5(13):2717-2724.
doi: 10.1182/bloodadvances.2021004288.
Comorbidities are risk factors for hospitalization and serious COVID-19 illness in children and adults with sickle cell disease
Lana Mucalo[SUP] 1 [/SUP], Amanda M Brandow[SUP] 2 3 [/SUP], Mahua Dasgupta[SUP] 3 4 [/SUP], Sadie F Mason[SUP] 1 [/SUP], Pippa M Simpson[SUP] 3 4 [/SUP], Ashima Singh[SUP] 1 [/SUP], Bradley W Taylor[SUP] 5 [/SUP], Katherine J Woods[SUP] 6 [/SUP], Fouza I Yusuf[SUP] 1 [/SUP], Julie A Panepinto[SUP] 2 3 [/SUP]
Affiliations
Abstract
Patients with sickle cell disease (SCD) are at high risk of developing serious infections, therefore, understanding the impact that severe acute respiratory syndrome coronavirus 2 infection has on this population is important. We sought to identify factors associated with hospitalization and serious COVID-19 illness in children and adults with SCD.We established the international SECURE-SCD Registry to collect data on patients with SCD and COVID-19 illness. We used multivariable logistic models to estimate the independent effects of age, sex, genotype, hydroxyurea, and SCD-related and -nonrelated comorbidities on hospitalization, serious COVID-19 illness, and pain as a presenting symptom during COVID-19 illness. As of 23 March 2021, 750 COVID-19 illness cases in patients with SCD were reported to the registry. We identified history of pain (relative risk [RR], 2.15; P < .0001) and SCD heart/lung comorbidities (RR, 1.61; P = .0001) as risk factors for hospitalization in children. History of pain (RR, 1.78; P = .002) was also a risk factor for hospitalization in adults. Children with history of pain (RR, 3.09; P = .009), SCD heart/lung comorbidities (RR, 1.76; P = .03), and SCD renal comorbidities (RR, 3.67; P < .0001) and adults with history of pain (RR 1.94, P = .02) were at higher risk of developing serious COVID-19 illness. History of pain and SCD renal comorbidities also increased risk of pain during COVID-19 in children; history of pain, SCD heart/lung comorbidities, and female sex increased risk of pain during COVID-19 in adults. Hydroxyurea showed no effect on hospitalization and COVID-19 severity, but it lowered the risk of presenting with pain in adults during COVID-19
. 2021 Jul 13;5(13):2717-2724.
doi: 10.1182/bloodadvances.2021004288.
Comorbidities are risk factors for hospitalization and serious COVID-19 illness in children and adults with sickle cell disease
Lana Mucalo[SUP] 1 [/SUP], Amanda M Brandow[SUP] 2 3 [/SUP], Mahua Dasgupta[SUP] 3 4 [/SUP], Sadie F Mason[SUP] 1 [/SUP], Pippa M Simpson[SUP] 3 4 [/SUP], Ashima Singh[SUP] 1 [/SUP], Bradley W Taylor[SUP] 5 [/SUP], Katherine J Woods[SUP] 6 [/SUP], Fouza I Yusuf[SUP] 1 [/SUP], Julie A Panepinto[SUP] 2 3 [/SUP]
Affiliations
- PMID: 34196678
- DOI: 10.1182/bloodadvances.2021004288
Abstract
Patients with sickle cell disease (SCD) are at high risk of developing serious infections, therefore, understanding the impact that severe acute respiratory syndrome coronavirus 2 infection has on this population is important. We sought to identify factors associated with hospitalization and serious COVID-19 illness in children and adults with SCD.We established the international SECURE-SCD Registry to collect data on patients with SCD and COVID-19 illness. We used multivariable logistic models to estimate the independent effects of age, sex, genotype, hydroxyurea, and SCD-related and -nonrelated comorbidities on hospitalization, serious COVID-19 illness, and pain as a presenting symptom during COVID-19 illness. As of 23 March 2021, 750 COVID-19 illness cases in patients with SCD were reported to the registry. We identified history of pain (relative risk [RR], 2.15; P < .0001) and SCD heart/lung comorbidities (RR, 1.61; P = .0001) as risk factors for hospitalization in children. History of pain (RR, 1.78; P = .002) was also a risk factor for hospitalization in adults. Children with history of pain (RR, 3.09; P = .009), SCD heart/lung comorbidities (RR, 1.76; P = .03), and SCD renal comorbidities (RR, 3.67; P < .0001) and adults with history of pain (RR 1.94, P = .02) were at higher risk of developing serious COVID-19 illness. History of pain and SCD renal comorbidities also increased risk of pain during COVID-19 in children; history of pain, SCD heart/lung comorbidities, and female sex increased risk of pain during COVID-19 in adults. Hydroxyurea showed no effect on hospitalization and COVID-19 severity, but it lowered the risk of presenting with pain in adults during COVID-19